Alternative performance measures

This is a measure used by management and in calculations for bank covenants

Closest IFRS measure

Adjustments to reconcile to IFRS measure

Reason for use

Adjusted operating profit

Operating profit

Excludes exceptional items, acquisition-related expenses, primarily amortisation of business combination intangible assets, and other significant one-off items

The Group considers this to be an important measure of Group performance and is consistent with how the Group is assessed by the Board and investment community

Adjusted profit
before tax

Profit before tax

As per adjusted operating profit

As per adjusted operating profit

Adjusted profit
for the year

Profit for the year

As per adjusted operating profit and also excludes one-off exceptional tax credits or charges

As per adjusted operating profit

Adjusted earnings
per share

Earnings per share

As per adjusted operating profit and also excludes exceptional and one-off tax credits or charges

Adjusted earnings per share is used by management to understand the earnings per share of the Group after removing non-recurring items and those linked to combinations

Net debt

Cash and borrowings

Net debt is cash less gross bank loans, excluding transaction costs and lease liabilities

Net debt is cash less gross bank loans, excluding transaction costs and lease liabilities
This is a measure used by management and in calculations for bank covenants

Adjusted operating profit

2025
£'000

2024
£'000

Operating profit

21,625

2,952

Add back:

Amortisation on acquired intangibles

250

Exceptional costs of closure of MuCell business

946

15,178

Total

22,821

18,130

Adjusted profit before tax

2025
£'000

2024
£'000

Profit before tax

19,963

153

Add back:

Amortisation on acquired intangibles

250

Exceptional costs of closure of MuCell business

946

15,178

Total

21,159

15,331

Adjusted profit for the year

2025
£'000

2024
£'000

Profit for the year

22,639

(2,755)

Add back:

Amortisation on acquired intangibles*

187

207

Exceptional costs of closure of MuCell business

946

15,178

Deduct exceptional credit for recognition of deferred tax asset

(5,217)

Total

18,555

12,630

Adjusted earnings per share

2025
£'000

2024
£'000

Adjusted profit

18,555

12,630

Number of shares in issue

48,827,596

48,669,691

Adjusted profit/number shares in issue* 100,000

38.00

25.95

Net debt

2025
£'000

2024
£'000

Interest bearing loans and borrowings

45,511

34,602

Cash and cash equivalents

(13,982)

(10,534)

Net debt

31,529

24,068